CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Sanofi (SAN) to buy US oncology specialist Amunix for $1bn

By Jenni Reid

07:37, 21 December 2021

Sanofi logo on building exterior
French pharma firm Sanofi has been purchasing US businesses as it expands its assets within general medicines – Photo: 360b/Alamy

France’s Sanofi (SAN) has announced it will buy California-based immuno-oncology specialists Amunix Pharmaceuticals for around $1bn (£756m). 

The pharma giant said Amunix would give it a “promising pipeline” of T-cell engagers and cytokine therapies, with one cancer therapy – AMX-818 – expected to be in clinics early next year. 

The $1bn upfront payment will be followed by up to $225m on the completion of future development milestones.

“The Amunix technology platform utilizes a next generation smart biologics approach to precisely tailor-deliver medicines to become active only in tumor tissues while sparing normal tissues, thus bringing the promise of more effective and safer treatment options for cancer patients,” said Sanofi’s global head of research and development John Reed.

US acquisitions 

The acquisition follows Sanofi’s recent purchases of US firms Translate Bio, maker of mRNA therapeutics, for around $3.2bn, and Kadmon Holdings, developer of a recently FDA-approved treatment for chronic graft-versus-host disease, for $1.9bn. 


2,036.64 Price
-0.390% 1D Chg, %
Long position overnight fee -0.0196%
Short position overnight fee 0.0114%
Overnight fee time 22:00 (UTC)
Spread 0.30


0.61 Price
-0.490% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168


37,840.70 Price
+0.180% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00


15,863.50 Price
-0.830% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Sanofi is seeking to grow core assets within general medicines.

The French pharma company is currently working on a Covid-19 vaccine with GlaxoSmithKline, which it said showed “consistently strong immune responses” but which has faced numerous delays compared with other vaccines. 

In October, Sanofi reported double-digit sales growth in the third quarter and increased its full-year 2021 guidance.

Read more: Sanofi (SAN) and GlaxoSmithKline (GSK) announce positive booster data

Markets in this article

85.53 USD
0.31 +0.370%
85.53 USD
0.31 +0.370%

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading